sign in sign up
<<
Home , Androstadienone, Hyperforin, Stress hormone

SUBJECT INDEX VOLUME 23 NUMBER S2

A B Cigarette smoking, S150 Circadian salivary levels, S105 Abnormal neuroendocrine, S97 B12 vitamin, S140 Circannual melatonin, S108 Abstinent male alcoholics, S156 Beclomethasone-induced vasoconstriction Circuitry pharmacotherapy, S73–S75 Academia, S10 (BIV), S121 Clinical diagnosis, S115 Academically-striving countries, S59 Bed nucleus of the stria terminals, S111 Clinical Global Impression Scale, S116 ACE gene, S130 Behavior problems, S100 Clinical trials, S43 ACE I/D polymorphism, S106 Behavioral effects of NK1, S23 Clobazam, S3 ACTH secretion, S29 Behavioral endocrine responses, S119 Clonidine administration, S132, S139 Acute adolescent mania, S124 Benign intracranial hypertension, S136 Clorniphene, S78 Acute major depressive disorder, S113 Benzodiazepine withdrawal syndrome, Clozapine, S54, S116, S123, S135 Acute schizophrenia, S122 S124 Cocaine, S17, S46, S133 Addiction, S17, S102 Benzodiazapines, S56 Cognition, S51, S79, S92–S94 Administrative arrangements, S9 Benzothiophenes, S79 Cognitive aging, S94 Adolescent, S82 Bilateral grand mal seizure, S91 Cognitive dysfunction, S128 Adrenal hyperplasia, S60 Biochemical markers, S110 Cognitive functioning, S8 Adrenal insufficiency, S48 Biogenic amine systems, S43 Cognitive therapeutic considerations, S99 Adrenalectomy treatment, S145 Biological Psychiatry, S35 Collaboration, S58 ␤-, ␣2-adrenergic receptors, S3 , S70 Collegium International A2-adrenoceptor supersensibility, S139 Bipolar adolescents, S124 NeuroPsychopharmacologicum, S9 Adrenoceptor up-regulation, S138 Bipolar disorder, S3, S12, S64, S68, S75, S87, Comorbid psychiatric disorders of somatic Adverse early environment, S5 S107, S132 illness, S143 Affective disorders, S137 Blood metabolism, S123 Consultation-liaison psychiatry, S100 Aggression, S136, S151 Body, S8 Convulsive therapy, S91 ␬ agonists, S145 Body-mind interplay, S40 Corticotropin releasing factor, S1, S4, S29, AIDS, S19, S49–S51, S113 Bone mineral density, S34 S60, S77, S149 Alcohol-exposed children, S148 Brain, S92–S94 Corticotropin-releasing , S81 Alcohol ingestion in the afternoon, S117 Brain aging, S94 Corticotropin-releasing hormone system, Alcoholics, abstinent male, S156 Brain closure function, S152 S124 Algorithm-based treatment, S68 Brain damage, S86 Cortisol, S47 , S24, S40, S72 Brain development, S12, S70 CRF, S6 Allotetrahydrodeoxycorticosterone, S24 Brain circuits, S65 CRF cells, S111 Alzheimer’s disease, S8, S48, S52, S94, S128 Brain functions, S140 CRF neurocircuits, S63 Ampakines, S84 Brain plasticity, S36 CRF antagonists, S5 Amphetamine receptor antagonists, S118 Brain redox systems, S52–S54 CRF1-selective antagonist, S119 Amphetamine, S17 Brain regional structures, S64 CRH hypothesis, S6 Amygdala, S77 Brasilian study, S114 CRH system, S76 ␤-Amyloid, S52 Bulimia nervosa, S104 CRH type-1 receptor antagonism, S119 Analgesic responses, S145 Business ethics, S16 Cultural formulation, S37 Androstadienone, S28 Cultural framework, S95 Angiotensin I-converting , S106 Cultural specificity, S45 Anorexia nervosa, S104 C Culture, S37 Anticonvulsant drugs, S3 Cyclic Amp response element binding Anticonvulsant theory, S89 C-6 glioma cells, S131 protein, S18 effect, S146 -calmodulin kinase type II, S18 Cytokines, S60 Antidepressant treatment, S26, S103 cAMP, S3 Antidepressant trials, S44 , S3 , S23, S42–S44, S74, S95 Carbohydrate tolerance, S80 Antioxidants, S52, S53 Carbon monoxide, S30 D Antipsychotic drugs, S32, S55, S73 CCK-4 induced panic, S157 Antipsychotic therapy, S32–S35, S134 Cell biology, S35 D-allele, S106 Antipsychotic treatment, S144 Cell communication, S15 Daylength variation rate, S108 Anti-saccade performance, S151 Central nervous system, S12, S92 , S25, S56 Anxiety, S61, S65, S77, S86, S133 Cephalalgia, S132 Delayed-type hypersensitivity, S105 Anxiety disorders, S5, S6, S56, S64, S76, S104 Cerebral function, S67 Dementia, S126, S136 metabolite, S26 Cerebralum®, S127/ Depressed men, S147 Anxiolytic-hypnotic drugs, S24 Cerebravascular disease, S127 Depression ideation, S139 Astrocytes, S131 Chang, S22 Depression, S26, S34, S35, S47, S57, S59–S61, Atenolol, S138 Channel blockers, S75 S62, S65, S76, S80–S83, S89, S101, S103, Attention deficits, S152 Channel openers, S75 S104, S121, S133, S138, S144, S153 drugs, S14 Chemosensory transduction, S27 Depression subtypes, S113 Atypical neuroleptics, S55 Child, S82 Depressive disorders, S44, S64, S95, S105, Autoimmune disorders, S30 , S24 S113, S115 Autonomic responses, S119 CHR, S49 Depressive patients, S130 AVP-neuropbysin, S50 Chronic depression, S113 suppression test (DST), Axis stress responses, S2 Chronic fatigue syndrome (CFS), S76, S114 S110

NEUROPSYCHOPHARMACOLOGY 2000–VOL. 23, NO. S2 © 2000 Elsevier Science Inc. and American College of Neuropsychopharmacology 0893-133X/00/$–see front matter 655 Avenue of the Americas, New York, NY 10010 PII S0893-133X(00)00124-X

NEUROPSYCHOPHARMACOLOGY 2000–VOL. 23, NO. S2 Subject Index S163

Dexamethasone treatment, S145 G 5-HT-1A receptor, S91 Deydroepiandrosterone, S40 Human sexuality, S94–S95 D-Fenfluramine challenge test, S89, S122 GABA mediated inhibition, S26 Hydrocortisone treatment, S124 DHEA, S46–S48, S127 GABAA receptor, S72 Hypercortisolism, S60 DHEA-S, S25, S127 GABAA receptors gene expression, S24 Hyperforin, S88 Diabetes, S106, S123 GABRA5 gene locus, S136 perforatum, S88 Diencephalic stimulation theory, S90 Gaddum, S22 Hyperprolactinemia, S33 Differential gender effects, S32 Gender, S32–S35, S123 Hypogonadal men, S147 Discomfort index, S109 Gender differences in brain stems, S64–S66 Hypothalamic-pituitary-adrenal (HPA) Diurnal cortisol, S19 Gender specific, S28 axis, S2, S6, S14, S29, S30, S35, S50, S60, DNA technology, S8 Gene expression, S15, S70 S65, S76, S88, S146 , S17, S35, S53, S93, S118 Gene-related peptide, S118 Hypothalamic-pituitary-gonadal (HPG) Dopamine , S148 General medicine, S102 axis, S66 Dopamine neurotransmission, S137 General practitioners, S98–S99, S102 hypothalamic-pituitary-thyroid (HPT) axis, Dopamine receptor antagonists, S118 Genetic association study, S136 S67, S69 Dopamine receptor D3, S137 Genetic enhancement, S18 Hypothalamo-pituitary-adrenal (HPA) Dopamine receptors D2, S137 Genetic risk, S12 system, S80 Doxorubicin, S118 Genetics, S7 Hypothalamus, S57, S91 Drug development, S13 Genital herpes, S31 Hypothyroidism, S106 , S32 Geomagnetic factors, S109 Drugs of abuse, S19 Geomagnetic field, S108 Dysthymic patients, S113 Geomagnetic index DST, S109 I Germany, S16 Globalization, S9, S20 I/D polymorphisms, S130 antagonists, S56 Idiographic fomulation, S95 E Glucocorticoid negative feedback, S65 IGF-1, S118 Immune function, S19 Early-onset schizophrenia, S126 Glucocorticoid receptor, S131 Glucocorticoid receptors antagonists, S59– Immune system, S18–S20, S101 Eating disorders, S25, S96, S104 Immunity, S31 Educational programs, S59 S61 , S49, S101 Impaired glucose tolerance, S123 EEG complexity changes, S125 Impulsivity, S134 EEG sleep, S82 Glucose tolerance, S123 Insomnia, S104 Efficacy, S42, S43 Glutamate, S93 Insurance, S16 Elderly men, S136 Glutamate mechanisms, S83–S87 Interferon-␣, S133 Elderly patients, S126 Glutamate synapse, S53 Intervention, S99 Electroconvulsive therapy (ECT), S69, S89– Glycemic peak delay, S123 Intracellular messengers, S3 S91, S127 Gonadal hormones, S109, S114 Intravenous drug use (IDU), S113 Electroconvulsive treatments, S62 Gonadal , S96, S109 Gonadectomy, S114 Intravenous infusion of sodium lactate, S135 ELISPOT technique, S110 Ischemic brain damage, S86 Emotional functioning, S8 Gonadotropins, S28 Emotional , S111 Government, S43 ␤-END, S117 Governmental agencies, S10 Endocrine dysfunction, S34 Grand mal seizure, S91 K Endocrine functions, S80–S83 , S82 Growth hormone-releasing hormone, S80, , S86 Endocrine system, S59 Kraepelin, S123, S140 Endogenous , S128 S81, S82 Environmental factors, S109 GSK-3B, S38 Episodic psychiatric disorders, S3 Gynecology and psychiatry, interface , S56, S92 between, S96–S98 L , S41, S66, S92–S94, S107 ␤ Lamotrigine, S3 Estrogen receptor , S92 H Latency, S146 Estrogen replacement therapy, S94 LC/NE system, S76 Estrogen supplementation, S153 Haloperidol, S54, S89, S150 Learning, S18 Estrogen therapy, S126 Haloperidol treatment, S123 Learning disabilities, S106 Estrogen- link, S98 Health care, S7 Learning/memory performance, S114 Ethanol, S72 Health care aspects, S15–S16 Leeman, S22 Ethics, S16 Health care policy, S7 Legislation, S21 Euthyroid psychiatric subjects, S142 Healthy smokers, S134 , S68 Evolution, S12 Help-seeking Pathways, S95 , S39, S57, S62, S69 Experimental psychopathology, S35 Heterosexuals, S120 Lithium prophylaxis, S87 High melatonin excretors, S107, S138 Lithium response, S124 High risk subjects, S117 Lithium treatment, S156 F High-resolution imaging, S126 Long-term depression, S17 Hippocampal CA1 pyramidal cells, S92 Long-term potentiation (LTP), S17, S125 Federal Drug Administration, S44 Hippocampal circuitry, S92 Lordosis quotient, S112 Female depression, S130 Hippocampus, S17, S38, S90 Low melatonin depressives, S140 Female rat brain, S109 Hippocrates, S100 Low melatonin excretors, S107, S138 Female rats, S112 HIV, S18, S19 Low risk subjects, S117 Female Sprague-Dawley rats, S109 HIV-1 infection, S51, S133 Low serum triiodothyronie, S142 Fibromyalgia, S76 Hormonal interventions, S14 Lymphocytes, S110 First episode schizophrenia, S110 Hormonal replacement therapy, S14, S45, , S26, S130 S66 Forced migrants, S143 Hormones, S18–S20, S56–S57 M France, S15, S21 HPA axis, S111 Free radicals, S52 HPA system, S32, S130 Maghrebian psychiatry, S21 Functional brain imaging, S77 HPA-axis, S117 Magnetic resonance spectroscopy, S90, S126 Functional imagery, S15 5-HT3 receptor, S71 Major depressive disorder, S44, S64, S105, Functional imaging, S54 5-HT receptor sub-types, S115 S113, S115

S164 Subject Index NEUROPSYCHOPHARMACOLOGY 2000–VOL. 23, NO. S2

Major psychiatric disorders, S136 Neuroendocrine system, S91 Physical disorders, S155 Male depression, S130 Neuroendocrine tests, S87–S89 Physical , S111 Male dysthyma, S147 Neurogenesis, S38 Plasma cortisol levels, S105 Management of depression, S103 Neuroimaging, S64 Plasma , S24 Manic depression, S39, S106 Neuroleptics, S107 Plasma prolactin, S150 , S130 Neuromodulators, S74 Polymorphisms, S154 Maternal care, S13 Neuronal changes, S8 Postpartum cycloid, S97 Medical ethics, S16 Neuropathogenesis, S133 Postpartum depression, S116, S121 Mediterranean, S20–S21, S45 Neuropeptide Y (NPY), S61, S81, S118 Postpartum psychoses, S97 Medullary neurons, S111 Neuropeptides, S61–S63 Postraumatic stress disorder (PTSD), S76, Melatonin, S107, S108, S139, S140, S154 Neur ophysiological evaluation, S132 S105, S120, S121 Memory, S18, S140 Neuroplasticity, S38 Potassium currents, S75 Memory training, S106 Neuroprotection, S70 Prediction, S87 Menopause, S45, S98, S153 Neuroprotective activity, S118 Prefrontal cortex, S84 Menstrual cycle, S40, S155 Neuroprotective effects, S39 Pregnadiendione, S28 Menstrual dysfunction, S33 Neuropsychiatry, S9–S11 , S39 Menstrually-related disorders, S26 Neuropsychological pattern, S120 Premenstrual dysphoric disorder (PMDD), Mental and neurological illnesses, S104 Neuroreceptor PET/SPECT imaging, S155 S45, S96, S97, S122, S154 Mental disorders, S24–S27, S102 Neuroregulatory effects, S96 Premenstrual syndrome (PMS), S4, S45, S97, Mental health, S98 Neurosteroidogenic , S70 S112, S156 Mental health advocacy, S11 , S14, S24–S27, S39, S40 Primary care, S98, S99, S100, S102 Mental health programs, S9 Neurotensin (NT), S62, S118 PRIME-MD modules, S101 Mental health responsibility, S98 , S74 Problem-oriented practical review, S100– Mental health services, S999, S102 Neurotrophic actions, S78 S104 Mesolimbic dopamine system, S17 Neurotrophic factors, S62 Processing deficits, S128 Metabolic functioning, S15 , S134 , S41, S96, S116 Metabolic syndrome, S76 Nicotine nasal spray, S150 Progesterone metabolites, S40 Metabotropic glutamate receptor agonists, Nitric oxide, S30 Progesterone therapy, S156 S84, S86 NMDA receptors, S85 Progestins, S66 Metabotropic glutamate receptors, S86 Nocturnal thyroid-stimulating-hormone, , S41 Metastatic breast cancer, S19 S80 Prolactin release, S90 Methamphetamine, S52 Noncognitive psychiatric symptoms, S126 Prolactin response, S144 Methysergide, S145 Nongovernmental agencies, S10 Prolactin-sparing antipsychotic drugs, S33 Middle East, S20–S21, S46, S58 Noradrenaline, S62 Prolactinernia, S110 Mind, S8, S79 , S69, S74 Prozac, S142 Mnestic block syndrome, S129 Norepinephrine system, S1–S3 Psoriasis, S76 Modern psychology, S100 Norepinephrinergic antidepressants, S130 Psychiatric care, S95 Molecular genetics, S8 Normal ovarian endocrine, S97 Psychiatric diagnosis, S95 Monoamine neurotransmitters, S66 North Africa, S21 Psychiatric disorders, S71, S140 Monoamine transmitters, S53 Novel antidepressant interventions, S20 Psychiatry, S99, S100 Monotherapy, S134 Novel antipsychotic, S155 Psychiatry and gynecology, interface Mood, S77, S82 between, S96–S98 Mood disorders, S5, S6, S67, S68, S88, S116 Psychobiological reactions, S144 Mood disorders in women, S44–S45 O Psychological disorders, S155 Mood enhancing properties, S47 Psychological evaluation, S132 Mood modulators, S66–S69 Obsessive compulsive disorder, S36, S98, Psychoneuroendocrinology of stress, S29– Mood stabilizers, S38–S39, S75 S132 S32 Mood symptoms, S66 Octreotide, S136 Psychopathology, S36, S148 Morocco, S37 , S150 Psychopharmacological approaches, S104 Morphine, S113 Operational arrangements, S9 Psychoses, S116 Morphine orlorazepam withdrawal, S149 Oral contraceptives, S24, S24 Psychosexual development, S142 Mouse cerebral hemispheres, S131 Osteoporosis, S34 Psychosocial maturity, S100 Multidisciplinary, S35–S37 Outcome indicator, S142 Psychotherapeutic, S99 Multinational study, S154 Ovarian function, S33 Psychotic depression, S6 Multiple chemical sensitivity syndrome Ovariectomy, S114 Psychotic features, S120 (MCS), S114 Oxidative stress, S54 Psychotic major depression, S56 Multiple receptor targets, S73 Psychotropic drug action, S54 Multiple synapses, S14 Psychotropic drug use, S75 Multisystems, S73–S75 P Psychotropic medications, new, S12–S13 Myristoylated alanine-rich C kinase Public health care, S15 substrate, S38 Panic anxiety, S135 Panic disorder, S24, S157 Parameters, S20 Q N , S133 PAT brain mitochondria, S131 QA/QC parameters, S46 N-Acetyl aspartyl glutamate, S85 Patient needs, S100 Quality assurance, S7, S45–S46 Nasal pathway to the brain, S27–S28 Patient sampling, S42 National Alliance for the Mentally Ill, S11 Pavlov, I.P., S152 National Institute of Mental Health, S67 Peptides, S81 R Neocortex, S18 Perimenopause, S98 Nepal, S148 Peripheral nervous system, S70 R121919, S119, S149 Neuroactive steroids, S26, S70–S73 P-Chlorophenylalanine, S114 Raloxifene, S78 Neurocognitive functioning, S150 Pharmacokinetic observations, S119 Rat brain, S118 NeuroCybernetic Prosthesis System, S144 Pharmacological therapies, S104, S153 Rat hippocampus, S125 Neurodegenerative diseases, S127 Phencyclidine, S83, S86 Rearing behavior, S63 Neuroendocrine challenge, S115 Phenomenology, S123 , S1, S2 Neuroendocrine observations, S119 , S27–S28 Recovery sleep, S82 Neuroendocrine responses, S51, S149 Phosphatidylinositol, S3 Refugees, S143

NEUROPSYCHOPHARMACOLOGY 2000–VOL. 23, NO. S2 Subject Index S165

Rehabilitation, S143 Sleep, S80–S83, S146 Thyroid hormone receptors, S69 Religion, S99 Sleep deprivation, S80, S82, S146 , S57, S66–S69 Religious practice, S37 Sleeping disorders, S104 Thyrotropin-releasing hormone, S57 Repetitive transcranial magnetic Slow wave sleep, S81 Thyroxine, S66 stimulation, S20 Social isolation, S148 T-maze, S36 Reproductive events, S40 Social-Stress Disorders (SSD), S143 Tobaloperidol, S122 Reproductive hormones, S65 Sodium , S3, S135 Topiramate, S3 Reproductive-related disorders, S14 Somatic diagnoses, S101 Total sleep deprivation, S82 Research agenda, S58 Somatic intersexuality, S142 Transcranial magnetic stimulation, S146 Rhesus macaques, S113 Somatic symptoms, S101 Transcription factors, S52 Rhett’s Syndrome, S8 Somatophorm disorders, S142 Transcultural Psychiatry, S35 Risk factor, S121 Somatostatin, S81 Transsexual patients, S120 , S33, S120 Specific behavioral actions, S42 Treatment, S84 Russia, S143 Specific estrogen receptors modulators, S78– antidepressants, S2, S42, S56 Russian hospitals, S142 S79 , S57, S66, S68 Spiritual psychiatry, S35 Triphenylethylenes, S79 Spirituality, S99, S100 Trophic actions, S70 S Spirituality and mental health, S99–S100 Trophynotropine “Adement,” S128 SSRIs, S112, S153 Trophynotropine group, S127 Salivary cortisol levels, S153 St. John’s Wort, S88 depletion, S115 Schizophrenia, S12, S32–S35, S54, S55, S62, hormone action, S71 S83, S85, S86, S89, S92, S122, S123, S135, Steroids, S39–S42 S150 3␣-, S5␣-tetrahydroprogesterone, S25 U Schizophrenic patients, S107, S144, S150 Stimulant abuse medications, S155 Schizotypy, S152 Stress, S18, S29–S32, S50, S53, S59, S60, S61, UNICEF, S9 Schwann cells, S70 S77, S101 Unipolar major depression, S68 Scrizotypy, S151 Stress control, S29 Seasonal bimodal pattern, S108 Stress hormone systems, S6, S80 Seasonal pattern of melatonin secretion, Stress hormones, S129, S148 V S108 Stress reduction, S4 Secularization, S21 Stress responses, S13, S76 Vagus nerve stimulation, S144 Seizure, S90 Stress sensitization, S32 Val108Met, S151 Selective estrogen receptor modulators Stress-induced disorders, S76–S77 Valproate augmentation, S134 (SERMs), S112 Stress-related hormones, S53 Vasoactive IC drugs, S122 Selective NRI, S2 Substance abuse, S102 activity, S140 Selective serotonin reuptake inhibitors , S22–S23, S29, S110 , S1 (SSRIs), S1, S42, S45, S56, S66 Substance P antagonists, S22–S23 Ventricular abnormality, S97 Self reported sleep disorders, S109 Subtype synapse, S14 Vigabatrin, S157 Self-hypnosis, S31 Suicidal ideation, S139 Vitamin B12, S140 Serotonergic antidepressants, S130 Survival, S19 Vomeronasal organ, S27 Serotonergic system, S50 Synapse-targeted psychopharmacology, Vomeropherins, S27 Serotonergic transmission, S91 S54–S56 Von Euler, S22 Serotonin, S29, S62, S69, S73, S74, S84, S96 Synaptic plasticity, S17–S18, S53 Vulnerability to medical illness, S5 Serotonin 2A receptor, S92 Synaptic spines, S53 Vulnerability to psychiatric illness, S5 Serotonin (5-HT), S110 Synaptogenesis, S38 Vulnerability to substance abuse, S5 Serotonin deficiency, S112 Serotonin receptors, S109 Serotonin reuptake inhibitors, S122 T W Serum levels, S140 Sex difference, S44 Tamoxiphen, S78 Wingless INT-1 signalling, S38 Sex steroid-related aggression, S122 Target genes, S70 Wistar rats, S135 Sex steroid-related genes, S154 TBE glucocorticoid receptor, S131 Word fluency, S107 Sex steroids, S96 , S28, S56 World Association of Social Psychiatry, S9 Sexology, S122 Testosterone levels, S136, S147 World Federation of Biological Psychiatry, Sex-specific events, S44 Testosterone replacement, S147 S9 Sexual disorders, S95, S122 Therapeutic potential, S22 World Federation of Mental Health, S9 Sexuality, S94 Thyreotropin, S156 World Health Organization, S9 Signal transduction, S15 Thyroid disturbances, S105 World Psychiatric Association, S9, S10, S58, Single receptor targets, S73 Thyroid function, S67, S115 S59